Chemotherapy-induced Neutropenia Clinical Trial
Official title:
Real World Study of PEGylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Prevention of Chemotherapy-induced Neutropenia
The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.The primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade IV neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02643901 -
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02251977 -
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
|
Phase 3 | |
Terminated |
NCT02454530 -
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
|
||
Active, not recruiting |
NCT02104830 -
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients
|
Phase 3 | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Active, not recruiting |
NCT03294577 -
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
|
Phase 3 | |
Not yet recruiting |
NCT03701841 -
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
|
||
Completed |
NCT00776165 -
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
|
Phase 3 | |
Completed |
NCT03251768 -
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
Completed |
NCT04134429 -
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
|
||
Completed |
NCT04227990 -
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
|
Phase 2 | |
Completed |
NCT03102606 -
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
|
Phase 3 | |
Completed |
NCT01569087 -
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients
|
Phase 2 | |
Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
Completed |
NCT04460079 -
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
|
||
Recruiting |
NCT02725606 -
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
|
Phase 1 | |
Completed |
NCT02692742 -
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
|
Phase 2 | |
Completed |
NCT02532712 -
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01516736 -
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
|
Phase 3 |